|
|
18 April 2018 |
Advanced Medical Solutions Group plc
(“AMS”, the “Company” or the “Group”)
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors and PDMRs under the Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’) on 13 April 2018. The vesting period of these options is subject to certain performance criteria over a three year period.
|
Director/PDMR |
Options prior to grant |
Options granted |
Resultant holding |
|
Chris Meredith Chief Executive Officer |
421,440 |
90,344
|
511,784
|
|
Mary Tavener Chief Financial Officer |
327,825
|
69,888
|
397,713
|
|
Simon Coates PDMR |
69,524
|
14,751 |
84,275
|
|
Rose Guang PDMR |
143,355 |
19,844
|
163,199 |
|
Eddie Johnson PDMR |
89,158 |
19,603
|
108,761 |
|
Pieter van Hoof PDMR |
89,641 |
18,659
|
108,300 |
|
Rebecca Walmsley PDMR |
73,082 |
19,032
|
92,114 |
|
Jeffrey Willis PDMR |
126,031 |
30,647
|
156,678 |
|
Cathy Tomlinson PDMR |
Nil |
18,383 |
18,383 |
Advanced Medical Solutions Group plc also announces that on 13 April 2018, the Board, following a recommendation from the Remuneration Committee, granted new share options to the following Directors under the Advanced Medical Solutions Deferred Annual Bonus Plan (the ‘2014 DAB’).
This award is in respect of the part of their bonus that the Directors and PDMRs are compulsorily required to defer for the 2017 financial year. These options vest at the end of three years.
|
Director/PDMR |
Options prior to grant |
Options granted |
Resultant holding |
|
Chris Meredith Chief Executive Officer |
83,384 |
21,749 |
105,133 |
|
Mary Tavener Chief Financial Officer |
55,728 |
14,021 |
69,749 |
|
Simon Coates PDMR |
7,744 |
3,117 |
10,861 |
|
Rose Guang PDMR |
17,198 |
4,072 |
21,270 |
|
Eddie Johnson PDMR |
16,244 |
4,089 |
20,333 |
|
Pieter van Hoof PDMR |
14,826 |
3,983 |
18,809 |
|
Rebecca Walmsley PDMR |
5,181 |
3,483 |
8,664 |
|
Jeffrey Willis PDMR |
21,094 |
5,950 |
27,044 |
|
Cathy Tomlinson PDMR |
Nil |
2,573 |
2,573 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 90,344 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 21,749 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Mary Tavener |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 69,888 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 14,021 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Simon Coates |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 14,751 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 3,117 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Rose Guang |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 19,844 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 4,072 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Eddie Johnson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 19,603 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 4,089 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Pieter van Hoof |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 18,659 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 3,983 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Rebecca Walmsley |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 19,032 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 3,483 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Jeffrey Willis |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 30,647 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 5,950 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Cathy Tomlinson |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Grant of 18,383 options under the Advanced Medical Solutions Long Term Incentive Plan on 13 April 2018 · Grant of 2,573 options under the Advanced Medical Solutions Deferred Annual Bonus Plan on 13 April 2018 |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a |
||||
|
e) |
Date of the transaction: 13/04/2018 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
– End –
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Philippa Gardner |
AMS@consilium-comms.com |
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Patrick Robb / Gary Clarence |
|
About Advanced Medical Solutions Group plc – see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.
This information is provided by RNS
END
DSHLIFSTSFITLIT